Independent academic projectNot an official Nemaura Medical website
NEMAURACOMPANY RESEARCH PROFILEContact Us
Menu

Medical technology · Company profile

Making glucose
visible—without needles.

Nemaura Medical Inc. is a small medical technology company focused on wearable diagnostic devices and digital programs for diabetes, pre-diabetes and metabolic health.

Explore the technology ↗Read About Us
2013Incorporated
LoughboroughUK operations
NMRDOTC market symbol
GLUCOSE SENSORLIVE
Daily-wear patchNeedle-free
Current trend5 min
6.2 mmol/L
08:0012:0016:00
↗Data every 5 minutes
CE MarkClass IIb · Europe
SFDASaudi approval · 2023
U.S. pathwayFDA process reported
Commercial stageLimited rollout

01 / COMPANY

Small company.
Ambitious premise.

Nemaura sits at the intersection of wearable sensors, diabetes management and digital health coaching.

The core idea is simple: make glucose patterns easier to observe through a flexible skin-worn sensor—without the inserted filament used by conventional CGMs.

Founded / incorporated2013

Nevada incorporation records show 2013; some secondary company profiles cite 2011.

FounderDr. Faz Chowdhury

Long-serving chief executive and central technical leader.

Operating baseLoughborough, UK

Historically associated with Loughborough Science Park.

Company stageDevelopment → commercial

Pilots, partnerships and scale-up remain central.

02 / TECHNOLOGY

How sugarBEAT® works

A three-part wearable system designed to turn interstitial glucose measurements into frequent trend data.

01PATCH

Wear the patch

A thin, flexible, disposable adhesive sensor patch is applied to the skin for daily wear.

  • Soft silicone gel
  • About 1 mm thick
  • Up to 24-hour wear
02SENSE
⌁

Extract & measure

Low-level electrical currents draw interstitial fluid toward the skin surface for glucose measurement.

  • No inserted needle
  • Rechargeable transmitter
  • Reported service life around 2 years
03CONNECT
6.2mmol/L

See the trend

The transmitter sends readings to a mobile application at approximately five-minute intervals.

  • Near-real-time data
  • Trend visibility
  • Digital feedback

Important: sugarBEAT has been described as an adjunctive device. Insulin users may still require finger-stick calibration or confirmatory testing according to applicable labeling and clinician guidance.

PRODUCT ECOSYSTEM

From a sensor to a digital health platform.

01

sugarBEAT®

Flexible daily-wear glucose sensor, rechargeable transmitter and mobile application.

Core device
02

proBEAT™ + BEAT®

Non-invasive glucose data combined with AI-supported feedback, coaching and subscription programs.

Digital program
03

Miboko & wider uses

Explored metabolic wellness applications, hospital settings and broader analyte monitoring opportunities.

Exploration

03 / HISTORY

Key moments in the Nemaura story

2005

Related pharma roots

Nemaura Pharma Limited was formed around skin drug-delivery systems.

2013

Medical company formed

Nemaura Medical Inc. was incorporated in Nevada on December 24, 2013.

2018

Nasdaq listing

The company moved onto the Nasdaq Capital Market under NMRD.

2019

European milestone

sugarBEAT received a CE Mark as a Class IIb medical device.

2023

Saudi approval

SFDA approval followed reported pilots, partnerships and provisional orders.

2024

OTC transition

Nasdaq trading was suspended in January; the company accepted delisting and moved to OTC markets.

REGULATORY & COMMERCIAL

Progress is real.
Scale is the question.

Approval in one market does not automatically confer approval in another. Commercial orders and pilots also do not necessarily equal completed sales.

MarketReported statusReading
EuropeApproved CE Mark · Class IIb

A major regulatory milestone; rollout has nevertheless remained limited.

Saudi ArabiaApproved SFDA · 2023

Approval was reported alongside a licensee relationship and a provisional purchase order.

United StatesIn process FDA pathway reported

Company filings discussed a PMA or modular PMA path. This profile does not treat that as FDA approval.

CommercializationEarly Pilots + licensing

UK/Ireland licensing, U.S. digital-health activity and limited orders indicate activity, but not broad market adoption.

04 / FINANCIALS & OPERATIONS

A development story with material financial risk.

The latest audited annual figures located for this project cover the fiscal year ended March 31, 2023. They should not be read as current 2026 results.

FY2023 sales$77,044

Down from $503,906 in FY2022.

FY2023 net loss-$14.14M

Continued recurring losses.

Cash at Mar. 31, 2023$10.11M

Against significant notes payable.

Operating modelSmall · partnership-led
01DevelopSensor platform + digital programs
→
02ValidateClinical studies + regulatory work
→
03PartnerLicensees + commercial pilots
→
04ScaleContract manufacturing

Public profiles have shown widely varying employee estimates—from single-digit snapshots to roughly 36–38 people. The more durable conclusion is that Nemaura is a small company, and 2024 reporting described further outsourcing—including sensor production—to reduce overhead.

05 / PEOPLE

Leadership across a changing organization.

Small-company leadership teams change quickly. Names below are separated by level of current confirmation.

FOUNDER & CONFIRMED EXECUTIVE

Dr. Dewan Fazlul Hoque Chowdhury

Also known as Dr. Faz Chowdhury. Founder, chairman, president and chief executive officer; public documents have also listed him in principal financial and accounting roles. A June 2024 SEC information statement continued to identify him as CEO.

FounderChairmanPresidentCEO
Previously reported operational leadersHistorical / verify before reuse
Arash Ghadar, Ph.D.Former Chief Operating OfficerResigned September 20, 2024.
Jay WarnerHead of U.S. Commercial OperationsRole reported in earlier public profiles.
Thomas MortensenHead of E.U. Commercial Operations & MarketingRole reported in earlier public profiles.
Samantha SandersGlobal Head of Digital ProgramsRole reported in earlier public profiles.
Board & governance mentionsRecent + historical

Recent brief: Dewan Fazlul Chowdhury, Ruhksana Qayyum and Fuzail Jamall.

Past mentions: Thomas Moore, Timothy B. Johnson, Bashir Timol, Asim Butt and others.

Board composition should be checked against the most recent filing before publication as a current roster.

06 / ANALYSIS

What should a reader take away?

↗

THE OPPORTUNITY

Differentiated, user-friendly concept

  • Needle-free daily wear may appeal to people who avoid invasive sensors.
  • Digital coaching broadens the model beyond device sales.
  • CE and SFDA milestones demonstrate regulatory progress.
  • Licensing can extend reach without a large direct sales force.
↘

THE CHALLENGE

Execution, evidence and capital

  • Revenue has been minimal relative to operating losses.
  • Commercial pilots and orders have not yet shown broad adoption.
  • U.S. regulatory progress has faced delays and uncertainty.
  • OTC trading, staffing changes and going-concern language increase risk.

Nemaura Medical is best understood as a high-risk, development-to-commercialization medtech case: an intriguing technical proposition whose long-term value depends on regulatory follow-through, manufacturing execution, credible evidence and sustained funding.

RESEARCH NOTES

Sources & method

This site synthesizes the supplied assignment brief with public records. Company statements may contain forward-looking claims; SEC filings and regulator records should be given greater weight.

01
SEC · FY2023 Form 10-KBusiness, products, financial statements, risks and operations
02
SEC · January 2024 listing updateNasdaq delisting decision and OTC transition
03
SEC · June 2024 information statementCorporate information and chief executive confirmation
04
SFDA approval announcement · August 2023Saudi approval and product summary
05
SEC exhibit · Provisional MENA orderLicensee relationship and order conditions
06
UK Companies House · Nemaura Pharma LimitedRelated entity record and current company status
Educational disclaimer

This independent school project is not affiliated with Nemaura Medical Inc. It does not provide medical advice, investment advice, product instructions, or a recommendation to buy or sell securities. Product availability and regulatory status vary by jurisdiction.